Gastrodin attenuates rheumatoid arthritis by targeting KAT8 to inhibit the lactylation of H3K9

Gastrodin attenuates rheumatoid arthritis by targeting KAT8 to inhibit the lactylation of H3K9

Introduction: Rheumatoid arthritis (RA) is a chronic autoimmune disorder characterized by synovial inflammation and joint destruction, with limited therapeutic options. This study investigated the therapeutic potential of gastrodin (GAS), a natural phenolic glycoside derived from Gastrodia elata, in...

Full description

Saved in:
Bibliographic Details
Main Authors: Yufang Dai, Shunshun Wang, Jiayi Luo, Huiming Yu, Qianqian Du, Shuwan Hou, Minfu Liu, Shan Jiang, Huajiao Xu, Siyi Ye, Muhammad Farrukh Nisar, Haiyan Chen, Jiaqin Wu
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-03-01
Series:Frontiers in Pharmacology
Subjects:
rheumatoid arthritis
gastrodin
histone lactylation
KAT8
H3K9
glycolysis
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2025.1559744/full
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Introduction: Rheumatoid arthritis (RA) is a chronic autoimmune disorder characterized by synovial inflammation and joint destruction, with limited therapeutic options. This study investigated the therapeutic potential of gastrodin (GAS), a natural phenolic glycoside derived from Gastrodia elata, in targeting lysine acetyltransferase 8 (KAT8) to suppress histone H3K9 lactylation (H3K9la), a novel post-translational modification linked to inflammatory responses.Methods: The therapeutic effect of GAS on RA was verified by constructing RA models in vivo and in vitro. Molecular docking, surface plasmon resonance (SPR) assays, overexpression and silencing experiments were used to verify the results.Results:In vitro experiments demonstrated that GAS (10–20 μM) significantly inhibited lipopolysaccharide (LPS)-induced expression of pro-inflammatory cytokines (IL-6, MMP1, MMP13) in fibroblast-like synoviocytes (FLS) and THP-1 macrophages by downregulating glycolysis and lactate production. Molecular docking and surface plasmon resonance (SPR) assays confirmed KAT8 as a direct target of GAS, with a dissociation constant (KD) of 413.72 μM. Overexpression and silencing experiments revealed that GAS destabilized KAT8, thereby reducing H3K9la levels. In vivo, GAS (20 mg/kg) ameliorated joint swelling and synovial hyperplasia in a Sprague-Dawley rat adjuvant-induced arthritis (AIA) model, correlating with decreased H3K9la and IL-6 expression.Discussion: These findings establish GAS as a promising therapeutic agent for RA by modulating KAT8-mediated histone lactylation, providing new insights into epigenetic regulation of inflammation.
ISSN:1663-9812

Similar Items